Eli Lilly and Company, the manufacturer of Cymbalta, has established this voluntary Pregnancy Registry to learn about the pregnancy outcomes of women who have taken Cymbalta during pregnancy. In the future, the information gathered in this Registry may supplement other sources of data and assist clinicians and patients in weighing the risks and/or benefits of being treated with Cymbalta around the time of conception and during pregnancy. This drug is not approved for use during pregnancy. Women should notify their doctor if they become pregnant during therapy or intend to become pregnant during therapy.
The Cymbalta Pregnancy Registry is a registry that collects information from voluntary participants who are pregnant and who have been exposed to Cymbalta at any time during pregnancy. Women who are interested in enrolling may contact the Registry directly by calling 1-866-814-6975. This Registry is sponsored by Eli Lilly and Company and is managed by Kendle International Inc.
The primary goal of this Pregnancy Registry is to estimate the risk of major birth defects and other adverse pregnancy outcomes among pregnancies exposed to Cymbalta.
Due to the observational nature of this Registry, participation in the Registry will not influence or interfere with the treatment plan recommended by the patient's health care provider.
If you are interested in additional information, click on contact us for the Registry Coordinating Center.
For answers to specific questions about Cymbalta, please contact Eli Lilly and Company by dialing 1-800-LillyRx (1-800-545-5979).
The success of the Registry depends on the continued participation of health care providers and pregnant women who have been treated with Cymbalta, manufactured by Eli Lilly and Company. Support and information contributed from participating patients and Health Care Providers are greatly appreciated.
Thank you in advance for your time and participation. We welcome any questions you may have regarding The Cymbalta Pregnancy Registry.